Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients (Q44536684)
Jump to navigation
Jump to search
scientific article published on 24 July 2003
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients |
scientific article published on 24 July 2003 |
Statements
1 reference
Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients (English)
1 reference
Mark A Winters
1 reference
Ronald J Bosch
1 reference
Mary A Albrecht
1 reference
David A Katzenstein
1 reference
AIDS Clinical Trials Group 364 Study Team
1 reference
24 July 2003
1 reference
1 reference
188
1 reference
4
1 reference
537-540
1 reference
Identifiers
1 reference
1 reference